-
Anisomycin: JNK Agonist for Apoptosis Research
2026-08-24
Anisomycin is a JNK agonist and stress-pathway research tool used to examine JNK pathway activation in apoptosis. Its reported activity in DU 145, HL-60, fibroblast, and Ehrlich ascites carcinoma models supports controlled studies of apoptosis induction in cancer cells, while its broader ribotoxic effects require careful interpretation.
-
BCA Protein Quantification Kit: Practical Guide
2026-08-24
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit supports sensitive total-protein measurement when samples are dilute or contain many common ionic and non-ionic detergents. It is intended for scientific research workflows, including cell lysate normalization, and should not be used for diagnostic, clinical, or medical testing.
-
Iptacopan: A Decision Framework for Complement Assays
2026-08-23
Iptacopan and LNP023 provide a selective way to interrogate alternative complement amplification. This article presents an endpoint-triangulation framework linking factor B biology, complement assays, animal models, and translational interpretation.
-
Meropenem: Mechanism-Led Resistance Assays
2026-08-22
Meropenem is a β-lactam antibiotic carbapenem suited to mechanism-led antibacterial research. This article shows how to connect PBP biology, exposure-aware assay design, resistance phenotyping, and septicemia treatment research without confusing meropenem evidence with findings from newer β-lactam combinations.
-
CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer
2026-08-22
This study identifies a paracrine ANGPTL4–IQGAP1 pathway through which cancer-associated fibroblasts remodel prostate cancer cell mitochondrial metabolism and reduce chemotherapy sensitivity. By combining secretome proteomics, metabolic analysis, interaction assays, and drug screening, the authors connect the tumor microenvironment to OXPHOS-dependent resistance and nominate QGGP as a preclinical intervention strategy.
-
EGCG as a Systems-Level Antiangiogenic Probe
2026-08-21
(-)-Epigallocatechin gallate (EGCG) can be studied as more than an antioxidant or apoptosis reagent. This article develops a microenvironment-centered assay strategy linking angiogenesis, fibroblast activation, inflammation, adhesion, and translational limitations.
-
Relative vs Fractional Viability in Cancer Drug Testing
2026-08-20
Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of anticancer drug response: growth inhibition and cell killing. Its central practical contribution is a framework for measuring these effects separately and across time, improving interpretation of in vitro drug-response experiments.
-
Ridaforolimus at the mTOR–Senescence Frontier
2026-08-20
Ridaforolimus (Deforolimus, MK-8669) offers a mechanistically grounded way to interrogate mTOR-dependent growth, angiogenesis, and cell-fate decisions. This thought-leadership guide connects its cancer research profile with machine-learning-enabled senolytic discovery while defining practical assays, translational guardrails, and opportunities for more predictive experimental design.
-
Fingolimod and In Vivo T-Cell Engineering
2026-08-19
Fingolimod (FTY720) offers a mechanistic way to study lymphocyte trafficking, CNS signaling, and immune-cell access in advanced models. This article develops an assay-focused framework for interpreting FTY720 alongside magnetic CAR-T-mimicking platforms without conflating established MS pharmacology with emerging oncology hypotheses.
-
Brinzolamide Nanoemulsions: Permeation and Ocular Safety
2026-08-19
The reference study developed and screened 12 brinzolamide nanoemulsions, integrating transcorneal permeation with retinal-cell viability and two ocular-irritation models. Seven formulations outperformed a marketed suspension in an ex vivo bovine-cornea model, while NE6B and NE4C showed the most favorable combined safety profile.
-
SCH772984: ERK1/2 Assay Guide
2026-08-18
A practical, evidence-based guide to using SCH772984 (SKU A3805) in cell viability, proliferation, and cytotoxicity workflows. It connects ERK1/2 target engagement with assay controls, formulation handling, mutant MAPK models, and carefully bounded studies of radioresistance and ferroptosis.
-
KG-501 in CREB–TLR4 Assay Design
2026-08-18
KG-501 is a small-molecule CREB transcription inhibitor that can help researchers test whether macrophage-state changes in colitis-associated colorectal cancer depend on transcriptional coactivator signaling. This article translates the Liu et al. study into a cautious, decision-oriented framework for interpreting CREB, TLR4, and macrophage polarization assays.
-
L-Ornithine in OTC and CNS Metabolism Research
2026-08-17
L-Ornithine connects urea-cycle biochemistry with liver–brain-axis experiments, making it useful for both purified OTC assays and astrocyte toxicity models. This workflow-focused guide shows how to control solubility, solvent effects, treatment timing, and orthogonal readouts for more reproducible amino acid metabolism research.
-
Methoxy-X04: A Strategic Lens on AD Biology
2026-08-17
Methoxy-X04 connects brain-permeable amyloid imaging with mechanistic Alzheimer’s disease research, enabling translational teams to evaluate plaque burden, microglial clearance, and therapeutic response in context.
-
L-Ornithine and the Liver–Brain Axis
2026-08-16
L-Ornithine is more than a urea cycle intermediate: it is a practical probe for connecting hepatic nitrogen disposal with astrocyte metabolism. This thought-leadership article translates recent realgar-toxicity findings into assay strategy, experimental controls, and translational guidance for amino acid metabolism research.